The global car t-cell therapy market size was US$ 1.7 billion in 2021. The global car t-cell therapy market size is estimated to reach US$ 5.3 billion by 2030, growing at a compound annual growth rate (CAGR) of 13.5% during the forecast period from 2022 to 2030.
Chimeric antigen receptor (CAR) T-cell therapy is a new type of cancer treatment in which healthcare professionals modify T-cells in the lab and then inject them into a cancer patient's body, so they can find and kill cancer cells. It is a method of training the immune system to recognize cancer cells. This is called gene or cell therapy. CAR T-cell therapy is used to enhance the immune response against cancer cells.

Factors Affecting Marketing Growth

CAR-T cell therapy is mainly used for the treatment of lymphoma, acute lymphocytic leukemia, and multiple myeloma blood cancer which drives the growth of the global market.
An increase is due to rapidly expanding clinical trial activities and the recent commercialization of CAR-T cell therapy, which are anticipated to drive the growth of the global market.
The increase in awareness and rise in approval of new medicine of CAR T-cell therapy and promising drugs present in pipelines are expected to offer lucrative opportunities for the growth of the global market.

Impact on COVID-19 Analysis

COVID-19 had a negative impact on the global CAR T-Cell therapy market because priority is given to the patients for treatment. The discovery and development of CAR T-cell therapy medicine slowed down during the pandemic but did not stop. The significant reduction in clinical trials due to strict government guidelines against COVID-19 opposes the growth of the global CAR T-cell therapy market. The decline in people transit, closing of borders, and confinement of the population impacted the supply chains of these life-saving medical products in the CAR T-cell therapy market.

Regional Analysis

North America generated the highest revenue in 2021 due to the strong existence of key players and the availability of approved therapeutics with higher adoption of CAR T-cell therapies. Thus, driving the growth of the global market in the region.

Asia-Pacific is expected to witness the highest CAGR during the forecast period due to an increase in awareness regarding CAR T-cell therapy, the expected launch of CART drugs, and an increase in the target population. Thus, driving the growth of the global market in the region.

Leading Competitors
The prominent players in the global car t-cell therapy market are:
Sorrento Therapeutics Inc.
Miltenyi Biotech
Novartis AG
Juno Therapeutics
Intellia Therapeutics
Merck & Co
Gilead Sciences
Bristol-Myers Squibb
Caribou Biosciences
Autolus Therapeutics
Bluebird bio
Others
Segmentation Analysis
The global car t-cell therapy market segmentation focuses on Indication, End User, Drug Type, and Region.
Segmentation on the basis of Indication
Lymphoma
Acute Lymphocytic Leukemia
Others

Segmentation on the basis of End User

Cancer Treatment Centers
Hospitals

Segmentation on the basis of Drug type
Brexucabtagene Autoleucel
Axicabtagene Ciloleucel
Tisagenlecleucel
Others

Segmentation on the basis of Region
North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
UAE
Saudi Arabia
South Africa
Rest of MEA
South America
Brazil
Argentina
Rest of South America